Onorach Clinical Clinical Trial Support Services

Onorach Clinical is a clinical trial support company specialising in supporting our clients’ set up and delivery of clinical trials covering Phases I to IV. We’re also experienced in clinical trial services for medical devices and cell-based therapeutics.

We’re a young, fast-growing company focused on providing a fresh approach to our industry. Based in the north-east of Scotland, UK, but operating globally, we offer our clients the same high level of service anywhere in the world.

Tailored clinical trial support services

We pride ourselves on our growing reputation for our pro-active, tailored approach in delivering comprehensive and innovative solutions to the challenges faced in clinical trials.

A strong customer focus and detailed knowledge are at the heart of everything we do; that’s why we’re confident that we can help you deliver your clinical trial efficiently, cost-effectively and to the very highest standards.

Clinical trial site selection services

Our Right-Sites™ service is designed to identify, qualify and select the right sites for your clinical trial. This is a complex issue and involves the assessment of a number of factors including:

  • Adequate resources on-site for the study
  • Integrity of the research team (ICH-GCP compliant)
  • Accuracy in estimates of patient recruitment numbers and focus on early patient recruitment to meet the trial objectives and timelines
  • All research staff need to have a positive attitude towards the research study

An evaluation of these and other factors in our Right-Sites service makes for a stronger and more robust project and improves delivery of project time lines within budget.

Principal investigator selection services

Finding the optimal principal investigator (PI) is one of the biggest challenges in clinical trials. Not only must they be expert in the required therapeutic area, and have up-to-date experience in Good Clinical Practice (GCP), but they must also be enthusiastic about your trial and prepared to discuss issues with the CRO / sponsor as they arise to ensure the trial remains on time and on budget.

Even the best and most sought-after PIs only have so many hours in a day so we make sure that our PIs are ready to start the project when you are. Our Optimal» PI™ service addresses all of these issues to ensure the optimal progress of your clinical trial.

Clinical and medical liaison service

At Onorach we look beyond traditional sponsor / CRO models to provide the solutions that sponsors want for clinical trial challenges.

Onorach’s clinical and medical liaison service (OCMLS™) is one such solution and is designed to maintain the balance between clinical objectives and business, with Onorach providing the communication bridge between research consultants, sponsor staff and all members of the research team. This takes the communications burden away from the drug development company and ensures that timely communications on-site will prevent minor issues escalating into larger problems which will affect a sponsor and study time-lines.

At a time when the industry is undergoing dynamic changes OCMLS is one of the most effective means of shortening the time to peak study optimisation.

CRO services for drug development

All of the above services can be taken separately or in combination, and we also provide a full range of traditional CRO services such as monitoring and project management.

Our aim is to partner with sponsors in the drug development process, helping our clients address any issue related to the clinical trial process. For a relationship so close, it is important to choose the right partner. Our CRO-sponsorship relationship is one of a shared vision, complementary expertise and trust.

ICH-GCP compliant clinical trial support personnel

We firmly believe our people are our product; that’s why we invest in equipping our team with the most comprehensive training and skill sets available. Every member of our team is ICH-GCP compliant and works to the highest ethical and professional standards, and our team have experience in a wide range of therapeutic areas.

Call or email us now to find out how we can help you.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

Onorach Clinical Partners with Quantics

Onorach™ Clinical has recently formed a strategic partnership with Quantics Consulting to provide statistical services to Onorach™ clients. Quantics Consulting were chosen thanks to many years of statistical experience with life science companies. A.Professor Christene Leiper,

Onorach Clinical

Prospect House

Gemini Crescent Dundee Technology Park




United Kingdom

+44 1382 561048 www.onorach.co.uk

Onorach Clinical Images

Products and Services


White Papers

Related Projects

Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia

Doptelet® (avatrombopag) is one of the first thrombopoietin (TPO) receptor agonists to be approved in the US for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD).

5 June 2018

Lutathera (lutetium Lu 177 dotatate) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumours

Lutathera® (lutetium Lu 177 dotatate) is a peptide receptor radionuclide therapy (PRRT) indicated for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours.

5 February 2018

Faslodex (fulvestrant) for the Treatment of Advanced Breast Cancer

Faslodex (fulvestrant) is an oestrogen receptor antagonist indicated for the treatment of locally advanced or metastatic breast cancer.

25 January 2018

Eskata (hydrogen peroxide) for the Treatment of Raised Seborrheic Keratoses (SK)

Developed by Aclaris Therapeutics, Eskata™ (hydrogen peroxide) is an approved, topical, non-invasive treatment for raised seborrheic keratosis (SK).

11 January 2018

Luxturna (voretigene neparvovec) for the Treatment of Biallelic RPE65 Mutation-Associated Retinal Dystrophy

LuxturnaTM (voretigene neparvovec) is approved for the treatment of patients with biallelic RPE65 mutation-associated retinal dystrophy.

5 January 2018

Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington’s Disease

Austedo™ (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT 2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.

15 December 2017

KamRAB/KedRAB (rabies immunoglobulin human) for the Treatment of Rabies

KamRAB/KedRAB™ is a human rabies immunoglobulin (HRIG) indicated for the treatment of passive, transient post-exposure prophylaxis (PEP) of rabies infection. The drug was jointly developed by Kamada and Kedrion Biopharma.

7 September 2017

Tremfya (guselkumab) for the Treatment of Plaque Psoriasis

Tremfya™ (guselkumab) is a biologic approved for the treatment of adults living with moderate to severe plaque psoriasis.

25 July 2017

Baxdela™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Baxdela™ (delafloxacin) is a fluoroquinolone antibiotic drug indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI). The drug was discovered and developed by Melinta Therapeutics in partnership with Ligand Pharmaceuticals.

6 July 2017

Mydayis for the Treatment of Attention Deficit Hyperactivity Disorder

Mydayis is a CNS stimulant drug indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 years and above.

29 June 2017

Press Release

7 July 2011

Onorach™ Clinical has recently formed a strategic partnership with Quantics Consulting to provide statistical services to Onorach™ clients. Quantics Consulting were chosen thanks to many years of statistical experience with life science companies. A.Professor Christene Leiper,

Read more
27 April 2011

We are delighted to announce the launch of our new-look website. The website is designed to be easy to navigate and to give you the key information that you need when selecting a CRO for your clinical trial. Services for drug development, medical devices and biopharmaceuticals

Read more
15 November 2010

Onorach™ Clinical is pleased to announce that it will be presenting at the TB Drug Discovery Conference in Glasgow, UK, on 22-23 November 2010. Jan Anderson, Onorach's clinical / QA operations manager, will be presenting. Professor Christene Leiper, managing director and presiden

Read more

Regional Offices

Onorach Clinical

Prospect House

Gemini Crescent Dundee Technology Park




United Kingdom

+44 1382 561048 www.onorach.co.uk

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.